Product news

Share this article:

Japanese pharmaceutical company Daiichi Sankyo said the FDA has approved Azor, a drug to treat high blood pressure. Azor will be co-marketed in the US with Forest Laboratories. The drug combines active ingredients in two existing drugs used to treat hypertension, Benicar, also co-marketed in the US by Daiichi Sankyo and Forest, and Pfizer's Norvasc. Azor is approved for use in patients with high blood pressure, or hypertension, who initially failed treatment on other medications.
Daiichi Sankyo is a unit of Japanese pharmaceutical company Daiichi Sankyo Co.


Amylin Pharmaceuticals announced that the FDA has approved the SymlinPen120 and the SymlinPen 60 pen-injector devices for administering Symlin (pramlintide acetate) injection. These new pre-filled pen-injector devices feature simple, fixed dosing to improve mealtime glucose control.
Adams Respiratory Therapeutics announced that the FDA approved its supplemental New Drug Application for a grape-flavored formulation of Delsym Extended-Release Suspension. The company will immediately commence distribution of grape Delsym product to its trade customers.


The FDA announced the approval of Novartis' Lamisil Oral Granules for the treatment of tinea capitis, a fungal infection of the scalp, in children ages 4 years and older.


UCB and Sanofi-Aventis announced that Xyzal, a new once-daily medication used to treat indoor and outdoor allergies, as well as chronic idiopathic urticaria, is now available by prescription in the U.S. Xyzal is an oral antihistamine that has been shown to provide powerful allergy symptom relief. Xyzal is approved for use in adults and children 6 years and older.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.